Home » Stocks » MIRM

Mirum Pharmaceuticals, Inc. (MIRM)

Stock Price: $14.99 USD 0.11 (0.74%)
Updated Aug 3, 2021 2:05 PM EDT - Market open
Market Cap 440.05M
Revenue (ttm) n/a
Net Income (ttm) -132.49M
Shares Out 30.45M
EPS (ttm) -4.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $14.99
Previous Close $14.88
Change ($) 0.11
Change (%) 0.74%
Day's Open 14.90
Day's Range 14.70 - 15.56
Day's Volume 22,906
52-Week Range 13.90 - 27.43

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and GC Pharma have entered into an exclusive licensing agreement to develop and commercialize Mirum's maralixibat in South Korea.  Maralixibat is an investigatio...

1 week ago - Benzinga

FOSTER CITY, Calif. & YONGIN, South Korea--(BUSINESS WIRE)--Mirum and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea

1 week ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 weeks ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Piper Sandler's Virtual EASL Takeaway Day

1 month ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Presents Analyses from Its Rare Liver Disease Programs at the EASL International Liver Congress 2021

1 month ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Showcase Analyses from its Rare Liver Disease Programs at The International Liver Congress 2021

1 month ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 month ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors

1 month ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Showcases Maralixibat Transplant-Free Survival Data for PFIC and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting

2 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum to Present Maralixibat Data and Host Symposium at the 6th WCPGHAN Annual Meeting 2021

2 months ago - Business Wire

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -150.75% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the...

2 months ago - Zacks Investment Research

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

2 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021

3 months ago - Business Wire

FOSTER CITY, Calif. & BEIJING--(BUSINESS WIRE)--CANbridge and Mirum Enter into Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in Greater China.

3 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome

3 months ago - Business Wire

FOSTER CITY, Calif. & PARIS--(BUSINESS WIRE)--Mirum and Vivet Enter into Exclusive Worldwide Option and License Agreement for Gene Therapy Programs Targeting PFIC

3 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome

4 months ago - Business Wire

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -150.88% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for ...

4 months ago - Zacks Investment Research

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates

4 months ago - Business Wire

Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Upcoming Investor Conferences

5 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille Syndrome

6 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness Campaign

6 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients with Primary Sclerosing Cholangitis

6 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides Corporate Update

6 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021

6 months ago - Business Wire

Mirum Pharmaceuticals (MIRM) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies...

7 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies...

7 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Oberland Capital Announce Up to $210 Million Funding Arrangement

7 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Virtual Investor Day 2020

7 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2

8 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Upcoming Investor Conferences

8 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #AASLD--Mirum Data Presented at AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with ALGS Treated with Maralixibat

8 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Presents New Data From its Maralixibat and Volixibat Clinical Studies at AASLD Annual Meeting

8 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day

8 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Broadens Expanded Access Program for Maralixibat in Alagille Syndrome to Europe and Australia

8 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at the AASLD Annual Meeting

9 months ago - Business Wire

MoA reduces bile acid systemic levels. Potential utility across wide range of rare liver diseases.

9 months ago - Seeking Alpha

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the NASPGHAN Annual Meeting 2020

9 months ago - Business Wire

FOSTER CITY, Calif., Oct. 15, 2020 /PRNewswire/ -- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilit...

9 months ago - PRNewsWire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Investor Conferences in September

10 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum initiates rolling NDA submission for maralixibat for the treatment of cholestatic pruritus in patients with ALGS & launches EAP

11 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients with PFIC2 at Digital International Liver Congress

11 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference

11 months ago - Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates

11 months ago - Business Wire

Mirum Pharmaceuticals: Undervalued Rare Disease Player With Clear Path To Market

1 year ago - Seeking Alpha

About MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and p... [Read more...]

Industry
Biotechnology
IPO Date
Jul 18, 2019
Stock Exchange
NASDAQ
Ticker Symbol
MIRM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price forecast is 50.29, which is an increase of 235.49% from the latest price.

Price Target
$50.29
(235.49% upside)
Analyst Consensus: Strong Buy